Evidence map›Paper›PMID 39732571›Full record

ArticleTrends in molecular medicine2025

Targeting CDK2 to circumvent treatment resistance in HR

Leire Arrizabalaga, Esmeralda García-Torralba, Lorenzo Galluzzi, Aitziber Buqué

Abstract read
In one paragraph

Article in Trends in molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Computational and Experimental Analysis ofMolecules (Basel, Switzerland) · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Leire ArrizabalagaCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
Esmeralda García-TorralbaCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Department of Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain; Department of Medicine, Medical School, University of Murcia, Murcia, Spain; IMIB-Arrixaca, Murcia, Spain.
Lorenzo GalluzziCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: deadoc80@gmail.com.
Aitziber BuquéCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: abuquemartinez@gmail.com.

Funding

Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancerR01CA271915 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Lorenzo Galluzzi · 2023 to 2026
$2.9M
NCI NIH HHS R01 CA271915
6 · The paper itself

Abstract

Genetic and epigenetic defects of the p53 system have previously been associated with resistance to CDK4/6 inhibitors in women with HR

Indexed as

Antineoplastic AgentsBreast NeoplasmsCyclin-Dependent Kinase 2Drug Resistance, NeoplasmProtein Kinase InhibitorsAnimalsCellular SenescenceFemaleHumansTumor Suppressor Protein p53Antineoplastic AgentsCDK2 protein, humanCyclin-Dependent Kinase 2Protein Kinase InhibitorsTumor Suppressor Protein p53DREAM compleximmune checkpoint inhibitorsMDM2non-oncogene addictionRB1type I interferon

Identifiers

PMID39732571
PMCPMC13122099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.